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Oncogenic signalling and metabolic alterations are interrelated in cancer cells. mTOR, 
which is frequently activated in cancer, controls cell growth and metabolism. mTOR 
signalling regulates amino acid, glucose, nucleotide, fatty acid and lipid metabolism. 
Conversely, metabolic inputs, such as amino acids, activate mTOR. In this Review, we 
discuss how mTOR signalling rewires cancer cell metabolism and delineate how 
changes in metabolism, in turn, sustain mTOR signalling and tumorigenicity. Several 
drugs are being developed to perturb cancer cell metabolism. However, their efficacy as 
stand-alone therapies, similar to mTOR inhibitors, is limited. Here, we discuss how the 
interdependence of mTOR signalling and metabolism can be exploited for cancer 
therapy. 
 
Cancer cell growth is driven by aberrant signalling and metabolic reprogramming1. 
Cancer cells reprogramme their metabolism to ensure survival and proliferation in an 
often nutrient-scarce and stressful microenvironment. Metabolic alterations affect both 
catabolic pathways for production of ATP and precursor molecules and anabolic 
pathways for the synthesis of biomass. Many cancer-specific metabolic alterations have 
been described, including aberrant metabolism of amino acids, glucose, nucleotides, 
fatty acids and lipids. Metabolic reprogramming is often mediated by oncogenic 
signalling. In particular, mTOR signalling is commonly activated in tumours and 
controls cancer cell metabolism by altering expression and/or activity of a number of 
key metabolic enzymes2,3. Conversely, metabolic alterations, such as increased glucose 
or amino acid uptake, impact mTOR signalling. Thus, an integrated understanding of 
the crosstalk between mTOR signalling and cancer metabolism can aid in the 
development of novel therapeutic strategies. Here, we review recent findings on mTOR 
signalling, with a focus on cancer-specific metabolic alterations. We suggest that 
targeting both mTOR signalling and cancer cell-specific metabolic dependencies can be 
synergistic. 
 
Mechanisms of mTOR activation 
The atypical serine/threonine kinase mTOR is a master regulator of cell growth and 
metabolism. mTOR promotes anabolic processes such as ribosome biogenesis and 
protein, nucleotide, fatty acid and lipid synthesis and inhibits catabolic processes such as 
autophagy2. It is part of two structurally and functionally distinct complexes mTOR 
complex 1 (mTORC1) and mTORC2 (Fig. 1). mTORC1 contains mTOR, regulatory-
associated protein of mTOR (RAPTOR) and mammalian lethal with sec-13 protein 8 
(mLST8) and is rapamycin sensitive. mTORC2 contains mTOR, rapamycin-insensitive 
companion of mTOR (RICTOR), mammalian stress- activated MAPK-interacting 





Activation of mTORC1 by growth factors and nutrients 
The activation of mTORC1 is dependent on nutrients and growth factors. In response to 
nutrients, mTORC1 translocates from the cytoplasm to the lysosomal surface, where it 
is activated by growth factors via PI3K–AKT signalling. Growth factors, for instance, 
insulin, activate AKT4 via a cognate receptor, phosphoinositide- dependent kinase 1 
(PDK1) and PI3K (Fig. 1). AKT inhibits the TSC1–TSC2 complex5, which is a 
GTPase- activating protein (GAP) for the small GTPase RHEB6. GTP-bound RHEB 
directly binds and activates mTORC1 at the lysosome7,8 (Fig. 1). 
 
Nutrient-induced lysosomal translocation of mTORC1 
Nutrients, in particular amino acids, promote lysosomal localization of mTORC1 via the 
RAS-related GTP- binding proteins (RAGs)9, thereby enabling mTORC1 to encounter 
RHEB. RAGs are small GTPases that form obligate heterodimers. RAGA or RAGB 
associates with RAGC or RAGD. In the active state, GTP-bound RAGA or RAGB and 
GDP-bound RAGC or RAGD bind RAPTOR and thereby recruit mTORC1 to the 
lysosomal surface. The nucleotide binding status of the RAGs is tightly regulated by 
amino acids9 obtained from intracellular synthesis, protein turnover or extracellular 
sources via specific transporters (Fig. 1; for details, see following sections). Among the 
amino acids, leucine, arginine and glutamine are the most effective activators of 
mTORC1. Leucine and arginine bind to sestrin 2 and CASTOR1, respectively, 
ultimately to activate the RAGs and mTORC1 (for details, see Fig. 1, ref.10 and 
references therein). The lysosomal amino acid transporter SLC38A9 promotes 
mTORC1 activation by exporting essential amino acids to the cytoplasm11, where, for 
example, leucine can bind sestrin 2. Leucine export is stimulated by arginine binding to 
SLC38A9 (ref.11). 
Glutamine activates RAGs by promoting glutaminolysis. During glutaminolysis, 
glutaminase (GLS) and glutamate dehydrogenase (GDH) convert glutamine to α-
ketoglutarate (αKG), which ultimately activates mTORC1 via prolyl hydroxylases 
(PHDs) by promoting GTP loading of RAGB12 (Fig. 1). Leucine also stimulates αKG 
production by directly binding and allosterically activating GDH. Furthermore, glu- 
tamine activates mTORC1 independently of RAGs via the small GTPase ADP-
ribosylation factor 1 (ARF1)13 Amino acids also signal through folliculin (FLCN) and 
its binding partners FLCN-interacting proteins 1 or 2 (FNIP1 or FNIP2), which act as 
GAPs for RAGC and/or RAGD. 
 
Activation of mTORC2 by growth factors 
In contrast to mTORC1, growth factor signalling alone is sufficient to activate 
mTORC2, but the mechanism is still incompletely understood. Growth factors, for 
example, insulin, promote activation of PI3K and production of phosphatidylinositol-
(3,4,5)-triphosphate (PIP3), which in turn binds mSIN1 to relieve an mSIN1- mediated 
inhibitory effect on mTORC2 (ref.14). PI3K also activates mTORC2 by promoting 




mTORC1 and mTORC2 signalling effectors 
mTORC1 and mTORC2 regulate cellular growth and metabolism either through direct 
phosphorylation of key metabolic enzymes or indirectly through downstream signalling 
effectors. mTORC1 directly activates ribosomal protein S6 kinase (S6K) and inhibits 
eIF4E binding protein (4EBP) to increase translation, including translation of metabolic 
enzymes and metabolism-related transcription factors2. In addition, mTORC1 and S6K 
regulate metabolic enzymes directly (see below). mTORC2 promotes metabolism 
mainly via activation of AKT2. S6K and AKT not only regulate metabolic enzymes but 
also activate key metabolic transcription factors, such as MYC, hypoxia-inducible factor 
1α (HIF1α) and/or HIF2α, FOXO transcription factors and sterol regulatory element 
binding protein 1 (SREBP1)2.  
 
mTOR drives cancer metabolic reprogramming 
In many cancers, mTOR is often activated by mutations in its upstream regulators. 
These include gain-of-function mutation of PI3K3,16 and loss-of-function mutation of 
the tumour suppressor PTEN3. Furthermore, other oncogenic signalling pathways, such 
as RAS signalling, can activate mTOR signalling17. Inhibition of mTOR signalling, in 
particular, inhibition of mTORC1, has been explored as an anticancer strategy but with 
limited success. For example, rapamycin analogues (rapalogues) do not fully inhibit 
phosphorylation of the mTORC1 effector 4EBP and lead to compensatory upregulation 
of mTORC2–AKT activity18. As mentioned above, nutrient sensing plays a major role 
in activation of mTORC1. Therefore, changes in cancer cell metabolism and in levels of 
intracellular nutrients could also contribute to sustained mTORC1 activation. 
Conversely, changes in cancer cell metabolism are driven by mTOR signalling, and 
metabolic pathways promoted by mTOR signalling include amino acid, glucose, 
nucleotide, fatty acid and lipid metabolism2. This mutual determinism might provide 
novel vulnerabilities in cancer cells, which could be exploited to improve anticancer 
therapies. 
 
mTOR and amino acid metabolism 
Glutamine metabolism 
Glutamine is a non-essential amino acid, and yet, many cancer cells depend on 
extracellular glutamine for survival19. Glutamine serves as a nitrogen and carbon donor 
for the synthesis of amino acids, lipids and nucleotides, and it is used in cancer cells to 
replenish the tricarboxylic acid (TCA) cycle by anaplerosis20. Glutamine is imported 
into the cell via transporters such as SLC1A5, SLC38A1, SLC38A2 or SLC38A5 that 
are upregulated in many cancers21 (Fig. 2a). Pharmacological or biochemical inhibition 
of SLC1A5 reduces growth and mTORC1 activity in gastric22, prostate23 and triple-
negative breast24 cancer cells. However, blocking a single glutamine transporter might 
not necessarily be sufficient to prevent tumour growth, as compensatory upregulation of 
SLC38A1 occurs upon SLC1A5 knockdown in osteosarcoma and cervical cancer 
cells25. 
Both mTORC1 and mTORC2 signalling promote glutaminolysis through various 
mechanisms (Fig. 2a). mTORC1, via S6K, increases translation of MYC26, which in 
turn transcriptionally represses miR-23a and miR-23b27. miR-23a and miR-23b post-
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transcriptionally repress GLS27. Thus, mTORC1 positively regulates GLS expression to 
promote glutaminolysis. mTORC1 also promotes glutaminolysis by preventing sirtuin 4 
(SIRT4)-mediated GDH inhibition28 (Fig. 2a). mTORC2 might also favour 
glutaminolysis, in this case by inhibiting expression of glutamine synthetase (GS). 
Mechanistically, the mTORC2 effector AKT prevents nuclear localization of the 
transcription factors FOXO3 and FOXO4 to inhibit FOXO3-dependent or FOXO4-
dependent GS expression29. 
Interestingly, there is evidence that mTOR and glutaminolysis inhibitors have 
synergistic effects in inhibiting cancer cell growth. In a mouse model for lung squamous 
cell carcinoma (LSCC), chronic dual mTORC1 and mTORC2 inhibition (hereafter 
referred to as mTOR inhibition) blocks glycolysis. Chronic mTOR inhibition also 
provokes an adaptive increase in glutaminolysis that allows tumour cells to circumvent 
the loss of glycolysis and that results in resistance to mTOR inhibition30. 
Mechanistically, chronic mTOR inhibition in cancer cells leads to adaptive activation of 
AKT. This in turn inhibits glycogen synthase kinase 3β (GSK3β), thereby preventing 
the degradation of the transcription factors JUN and MYC and allowing GLS 
expression and glutaminolysis (Fig. 2a). Accordingly, resistance to mTOR inhibition 
could be overcome by addition of the allosteric GLS inhibitor CB-839 (ref.30), which 
effectively reduces growth of patient-derived LSCC xenografts30. 
With the aim of exploiting the dependence of cancer cells on glutamine metabolism, 
several inhibitors of glutamine uptake and/or catabolism are now being evaluated in 
preclinical and early-phase clinical trials. For example, a recently developed SLC1A5 
inhibitor efficiently reduces mTOR signalling and growth of lung, breast and colorectal 
cancer cells in vitro and of colorectal xenograft models in vivo31. The GLS inhibitor 
CB-839 is now in clinical trials for several solid tumours and haematological 
malignancies32,33 (Table 1). One ongoing clinical trial is currently evaluating CB-839 in 
combination with the mTORC1 inhibitor everolimus as a therapy for renal cell 
carcinoma (RCC)33 (Table 1). 
 
Arginine metabolism 
Arginine is a conditionally essential amino acid. Besides being used in protein 
synthesis, it serves as a precursor for polyamines, nitric oxide, creatine, proline and 
glutamate. Arginine is taken up into the cell mainly via SLC7A1. Increased expression 
of the transporter SLC7A1, which increases arginine uptake, has been reported in 
colorectal cancer34, breast cancer cell lines35 and hepatocellular carcinoma (HCC) 
lacking miR-122 expression, a negative regulator of SLC7A1 resistance. 
 
Synthesis of arginine and targeting potential. Arginine is produced by the urea cycle 
during the conversion of ammonia and aspartate into urea38. Carbamoyl phosphate 
synthetase 1 (CPS1) is located in the mitochondria and produces carbamoyl phosphate 
from ammonia and bicarbonate as the first step of the urea cycle. Together with 
ornithine, carbamoyl phosphate is used to generate citrulline. The rate-limiting enzyme 
in arginine synthesis is argininosuccinate synthetase 1 (ASS1), which forms 
argininosuccinate from aspartate and citrulline. Argininosuccinate lyase (ASL) then 
cleaves argininosuccinate into arginine and fumarate38 (Fig. 2b). 
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ASS1 expression is decreased or even abolished in many cancers including melanoma, 
RCC, HCC, glioblastoma (GBM), small-cell lung cancer (SCLC), pancreatic cancer and 
others39,40. Interestingly, ASS1 knockdown results in increased mTORC1 activity in 
osteosarcoma cells, potentially owing to increased aspartate levels41. Because ASS1-
deficient tumours rely on extracellular arginine for their survival, arginine deprivation is 
a therapeutic strategy for these cancers42. Several recombinant arginine-degrading 
enzymes have been developed and are now being evaluated in clinical trials43–47 (Table 
1). For example, recombinant human arginase (rhARG) cleaves arginine into urea and 
ornithine, and pegylated arginine deiminase (ADI-PEG20) degrades arginine by 
deaminating it to produce citrulline and ammonium. Treatment with rhARG reduces 
mTORC1 activity and induces cytotoxicity and apoptosis in non- SCLC (NSCLC) 
cells48. However, resistance to these drugs has already been observed. Cancer cells re-
express ASS1 to avoid reliance on extracellular arginine49. In the case of ADI-PEG20, 
treatment activates RAS signalling and subsequently PI3K–AKT signalling, which 
leads to stabilization of MYC. MYC in turn induces ASS1 expression by competing 
with HIF1α for ASS1 promoter binding sites42. Therefore, combining recombinant 
arginine-degrading enzymes with mTOR inhibitors might be beneficial in ASS1-
negative cancer types. Indeed, co-therapy of ADI-PEG20 with a PI3K inhibitor is more 
effective than either drug alone in preventing tumour growth in a mouse xenograft 
model42. 
 
Polyamine metabolism. Arginine serves as a precursor for polyamines, which are 
essential metabolites for cell proliferation50. Elevated levels of polyamines have been 
reported in cancer, and an extensive interplay between polyamines and mTOR 
signalling is beginning to emerge50. Arginine is cleaved by cytosolic arginase 1 (ARG1) 
or mitochondrial arginase 2 (ARG2) into ornithine and urea in the last step of the urea 
cycle. Ornithine decarboxylase (ODC), the rate-liming enzyme in polyamine 
biosynthesis and a MYC transcriptional target, then converts ornithine to putrescine, 
which is the immediate precursor for the polyamines spermidine and spermine51 (Fig. 
2b). mTORC1 signalling might be able to promote this pathway because ODC 
translation correlates with eIF4E activity52, which is controlled by the mTORC1–4EBP 
axis (Fig. 2b). Also, mTORC1 was shown to stabilize ODC (also known as ODC1) 
mRNA in RAS-transformed cells by promoting the association of the stabilizing 
mRNA-binding protein HuR (also known as ELAVL1) to the ODC transcript53. 
Although polyamines promote proliferation and tumour growth, several enzymes of 
arginine and polyamine metabolism, including ASS1, ARG2 and ODC, are suppressed 
in clear cell RCC (ccRCC)54. Overexpression of ARG2 and ASS1 decreases arginine 
and aspartate levels, respectively, and thereby inhibits growth of ccRCC cells. ASS1 
and/or ARG2 overexpression reduces tumour growth by various mechanisms, including 
reduction of mTORC1 activity54. The observed reduction in mTORC1 activity is most 
likely the direct consequence of reduced intracellular amino acid levels, including 
arginine, as observed in ccRCC xenografts upon ARG2 overexpression. 
The sequential synthesis of spermidine and spermine from putrescine requires 
aminopropyl groups, which are donated by decarboxylated S-adenosyl-methionine 
(decSAM) (Fig. 2b). The precursor of the decSAM-producing enzyme, 
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adenosylmethionine decarboxylase 1 (AMD1), is stabilized by mTORC1 in a PTEN-
driven mouse model of prostate cancer55. In addition, AMD1 expression is reduced in 
patients with cancer who have been treated with the mTORC1 inhibitor everolimus55. 
As of yet, it has not been determined whether mTOR inhibition can synergize with 
polyamine pathway inhibition to reduce tumour growth. This will be particularly 
interesting to investigate, as so far, numerous drugs targeting polyamine metabolism 
have been developed but have not yet advanced beyond phase II clinical trials50.  
 
Branched chain amino acids 
The branched chain amino acids (BCAAs) leucine, iso- leucine and valine are essential 
amino acids in mammals. Cells control BCAA levels via uptake and protein or amino 
acid catabolism. BCAAs, especially leucine, activate mTORC1 by various mechanisms 
(Fig. 1). 
The main BCAA transporter, SLC7A5, is highly expressed in many cancers including 
colorectal, liver and lung cancer56. It imports BCAAs and other essential amino acids in 
exchange for glutamine57. SLC7A5 expression, which is induced by oncogenic 
transcription factors, including NOTCH58, MYC59 and HIF2α60, results in mTORC1 
activation (Fig. 2c). For example, upregulation of SLC7A5 by HIF2α activates 
mTORC1 in RCC-derived cell lines60. In a PTEN-negative mouse model of T cell acute 
lymphoblastic leukaemia, NOTCH- mediated SLC7A5 expression activates mTORC1, 
which in turn reprogrammes metabolism58. Interestingly, as shown in lymphoma cells, 
mTORC1 inhibition by rapamycin treatment reduces expression of various amino acid 
transporters including SLC7A5 (ref.61). 
On the basis of the above observations, leucine starvation has been investigated as a 
cancer treatment strategy. Leucine deprivation inhibits proliferation and induces 
apoptosis in cancer cell lines62. Biochemical or pharmacological inhibition of leucine 
uptake in metastatic castration-resistant prostate cancer cell lines inhibits mTORC1 
signalling63. Some prostate cancers rely on androgen receptor (AR)-mediated SLC43A1 
expression for leucine uptake63. In line with the role of leucine as an mTORC1 
activator, anti-androgen treatment reduces both SLC43A1 expression and leucine levels, 
thereby decreasing mTORC1 activity. Lower intracellular leucine levels can elicit 
compensatory upregulation of SLC7A5 (ref.63). Such a feedback mechanism could 
normalize leucine levels and reactivate mTORC1. This possibly explains why the 
combination of rapamycin and anti-androgen therapy is more effective than either agent 
alone, as observed in a PTEN-deficient prostate cancer mouse model64. 
 
Branched chain amino acid catabolism. Once taken up into the cell, BCAAs can be 
used for the synthesis of biomass or catabolized to provide nitrogen and carbon groups. 
First, branched chain aminotransferase 1 (BCAT1) and BCAT2 catalyse the conversion 
(a transamination) of BCAAs to branched chain ketoacids (BCKAs) (Fig. 2c). BCKAs 
are then subject to irreversible oxidative decarboxylation by the BCKA dehydro- genase 
(BCKD) complex. Further oxidation ultimately leads to the formation of acetyl-CoA 
and succinyl-CoA to fuel the TCA cycle or to contribute substrates for fatty acid 
synthesis (Fig. 2c). BCAT1 levels are upregulated in GBM, HCC, breast cancer, 
colorectal cancer and chronic myeloid leukaemia (CML)65–69. However, the BCATs are 
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bidirectional enzymes (can also convert BCKAs to BCAAs), and either direction may 
be important in cancer cells. In GBM, BCAT1 predominantly deaminates BCAAs to 
produce BCKAs and glutamate65. By contrast, in breast cancer and CML cells, BCAT1 
uses BCKAs and glutamate to regenerate BCAAs and to activate mTORC1 (refs67,69). 
These findings indicate that increased BCAT1 expression alone is not sufficient to 
indicate the use of mTORC1 inhibitors, as sustained mTORC1 activation depends on 
the direction of BCAT1 function, and specific BCAT inhibitors have not been 
developed yet. 
 
mTOR signalling and glucose metabolism 
Glucose is the main source of cellular energy. Cancer cells increase glucose uptake and 
increase glycolytic flux to sustain growth and proliferation. In addition, aerobic 
glycolysis, a hallmark of cancer cells, provides a source of carbon moieties for anabolic 
processes including amino acid, lipid and nucleotide synthesis70. 
 
Glucose uptake and glycolysis 
mTOR signalling reprogrammes glucose metabolism by increasing the expression of 
glucose transporters and glycolytic enzymes71–73. Glucose transporter 1 (GLUT1; also 
known as SLC2A1) expression is increased in many cancers, including HCC and 
pancreatic, breast, lung and colorectal cancers74. In these cancers, mTOR signalling is 
also frequently activated3. mTOR signalling may activate GLUT1 expression via the 
transcription factors HIF1α and MYC71–73.  
Glycolysis converts glucose to pyruvate (Fig. 3). In the first step of glycolysis, 
hexokinase 2 (HK2) phosphorylates glucose to produce glucose-6-phosphate (G6P). 
Cancer cells often upregulate glycolysis by increasing HK2 expression or activity75. In 
prostate cancer cells, mTORC1 promotes glycolysis by increasing HK2 translation76. 
HK2 expression is also controlled at the transcriptional level by HIF1α and MYC71. 
Furthermore, MYC induces expression of several other glycolytic enzymes including 
phosphoglucoisomerase (PGI), phosphofructokinase (PFK) and enolase (ENO)71 (Fig. 
3). mTORC2, via AKT, phosphorylates HK2 to promote its association with 
mitochondria77. In GBM, mTORC2 increases HK2 activity75. mTORC2 also promotes 
glycolysis via inhibition of FOXO1 or FOXO3 and consequential activation of MYC, as 
shown in GBM73 (Fig. 3). The dependence of cancer cells on glycolysis led to the 
development of inhibitors of HK2. The glycolytic inhibitor 2-deoxyglucose (2-DG), of 
which the phosphorylated form inhibits HK2, increased patient survival in a phase I 
clinical trial for advanced solid tumours78. Recently, synergistic effects of 2-DG with 
inhibitors of MYC, PI3K or mTOR have been reported in lymphoma cell lines79. 
 
Pyruvate kinase 
Pyruvate kinase catalyses the formation of pyruvate, the final product of glycolysis (Fig. 
3). The tumour-specific isoform of pyruvate kinase, pyruvate kinase muscle isoform 2 
(PKM2), is upregulated in many cancers, including lung cancer, neuroblastoma, RCC 
and gastric cancer80. Knockdown of PKM2 inhibits proliferation in both in vitro and in 
vivo cancer models80,81. Of note, PKM2 is regulated by mTORC1 but also, via a 
positive feedback loop, stimulates mTORC1, thereby amplifying mTORC1 signalling 
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in cancer. MYC promotes PKM2 expression, to maintain glycolytic flux even under 
normoxia, in an mTORC1-dependent manner through heterogeneous nuclear 
ribonucleoprotein-dependent PKM2 mRNA splicing82. In turn, PKM2 activates 
mTORC1 through phosphorylation of the mTORC1 inhibitor prolinerich AKT substrate 
1 (PRAS40). Phosphorylated PRAS40 dissociates from RAPTOR, resulting in 
activation of mTORC1 (ref.83). Furthermore, serine, which acts as an allosteric activator 
of PKM2, sustains mTORC1 activity, at least in lung cancer cells. When serine is 
depleted, PKM2 is inhibited, and glycolytic intermediates consequently accumulate and 
are diverted to de novo serine synthesis. Thus, PKM2 also contributes to mTORC1 
activation by promoting de novo serine synthesis84. In addition, PKM2 not only is 
transcriptionally controlled by HIF1α downstream of mTORC1 (ref.85) but also 
regulates HIF1α transcriptional activity. PKM2 moonlights as a transcription co-
activator that increases HIF1α target gene binding. This creates a feedforward loop to 
sustain glycolysis in cancer cells86. Thus, mTORC1 and PKM2 might synergize to 
promote cell proliferation by driving glycolysis. Treatment with the PKM2 inhibitor 
shikonin shows promising results in advanced bladder cancer87 and gastric cancer cells 
both in vitro and in vivo88. However, a PKM2 inhibitor has not been tested in clinical 
trials, either alone or in combination with an mTORC1 inhibitor. 
 
Lactate and metabolic symbiosis 
Glycolytic cancer cells produce high amounts of pyruvate, which is converted to lactate 
by the bidirectional enzyme lactate dehydrogenase (LDH) (Fig. 3). LDH, via the 
regeneration of NAD+ during the conversion of pyruvate to lactate, allows cancer cells 
to sustain glycolysis71. 
This differential use of lactate and glucose can be observed within a tumour in a 
phenomenon known as metabolic symbiosis91,92. For example, hypoxic cancer cells 
distant from blood vessels import glucose, via GLUT1, to perform glycolysis91,92 and 
secrete excess lactate via monocarboxylate transporter 4 (MCT4). In turn, normoxic 
cancer cells in close proximity to blood vessels take up lactate via MCT1 to fuel the 
TCA cycle for ATP generation and for synthesis of amino acids, which leads to 
mTORC1 activation91,92 (box 1). Interestingly, mTORC1 inhibition by rapamycin 
disrupts metabolic symbiosis in this setting, leading to increased glucose uptake and 
glycolysis in normoxic cells and glucose deprivation and cell death in hypoxic cells91. 
This suggests that metabolic symbiosis might be targeted for anticancer therapy. For 
example, the MCT1 inhibitor AZD-3965 is currently being tested in patients with 
prostate cancer, gastric cancer and diffuse large B cell lymphoma93 (Table 1). Because 
mTOR promotes glycolysis and this can increase lactate flux, combination therapies of 
mTORC1 inhibitors with LDH or MCT inhibitors should be considered. 
 
mTOR and nucleotide metabolism 
Cancer cells have an increased demand for nucleotides. Nucleotides can be synthesized 
de novo or generated by the salvage pathway that recycles degradation intermediates of 
pre-existing nucleotides38. Formation of the pyrimidine and purine rings in nucleotides 
requires amino acids and ribose-5-phosphoribosyl-1-pyrophosphate (PRPP), among 
other substrates38 (Fig. 4). PRPP is generated from ribose-5-phosphate (R5P), which is 
 
 9 
produced in the pentose phosphate pathway (PPP), a pathway that is also under control 
of mTOR signalling. 
 
Pentose phosphate pathway 
The PPP metabolizes G6P and other intermediates of the glycolytic pathway in its 
oxidative and non- oxidative branches94 (Fig. 4). The oxidative PPP branch uses G6P to 
produce ribulose-5-phosphate and NADPH, for which the rate- limiting enzyme is G6P 
dehydrogenase (G6PD)94. G6PD levels and activity are elevated in many cancers, 
including gastric cancer, RCC, breast cancer, lung cancer and others95. The non- 
oxidative branch produces R5P, which is converted to PRPP by the enzyme 
phosphoribosyl pyrophosphate synthase 1 (PRPS1) or PRPS2 (ref.94). Both mTORC1 
and mTORC2 signalling promote the PPP. mTORC2 elevates G6P levels to fuel the 
PPP via AKT- mediated phosphorylation and activation of HK2 (ref.77) (Fig. 3). 
mTORC1 stimulates flux through both branches of the PPP by increasing expression of 
at least two PPP enzymes (Fig. 4). In an HCC model, mTORC1 increases flux through 
the PPP both by stimulating glycolysis, which provides PPP substrates, and by 
increasing levels of G6PD96 and R5P isomerase A (RPIA) (which generates R5P from 
ribulose-5-phosphate)96. As shown in mouse embryonic fibroblasts, mTORC1 
stimulates the PPP most likely through S6K- mediated activation of the transcription 
factors HIF1α and SREBP1 (ref.97) (Fig. 4). Consistent with this observation, PI3K 




Synthesis of the purine ring requires glutamine, glycine, aspartate, formyl-
tetrahydrofolate (f THF) and CO2. Purine rings are assembled directly on PRPP, 
resulting in the formation of inosine monophosphate (IMP) (Fig. 4). mTOR signalling 
stimulates purine synthesis indirectly, mainly by promoting enzymes that deliver 
substrates for the assembly of purine nucleotides. PRPS2 is the rate-limiting enzyme in 
purine synthesis and also provides PRPP for pyrimidine synthesis. mTORC1 and 
MAPK kinase 1 and/or MAPK kinase 2 induce PRPS2 expression through MYC and 
eIF4E99. mTORC1 also promotes purine nucleotide synthesis by upregulating the 
mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2)100. 
MTHFD2 mediates the formation of f THF, which donates carbon moieties for purine 
synthesis. 
 
Interestingly, purine nucleotides also regulate mTORC1 activity. Short-term deprivation 
of adenylate, but not guanylate, inhibits mTORC1 (ref.101). This inhibition (or activation 
after restoring adenylate levels) is TSC-dependent but RAG-independent and AMP-
activated kinase (AMPK)-independent101. Long-term guanylate starvation inhibits 
mTORC1 activity101,102, but the underlying mechanism is unclear. 
 
The mutual determinism of purine synthesis and mTOR activity is reflected in studies 
exploring pharmacological inhibition of the purine biosynthetic enzyme glycinamide 
ribonucleotide formyltransferase (GARFT; also known as GART) by AG2037. GARFT 
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inhibition results in tumour growth suppression in NSCLC xenografts, at least in part by 
inhibition of mTORC1 signalling102. Furthermore, mTORC1-dependent cancer cells 
have an elevated demand for nucleotides, and this vulnerability can be exploited by 
inhibition of guanine nucleotide synthesis. However, mizoribine, an IMP 
dehydrogenase (IMPDH) inhibitor, causes cancer cell death as a result of sustained 
mTORC1 activity in the absence of nucleotide synthesis103. Thus, in this situation, 
inhibition of guanine nucleotide synthesis alone is sufficient, and addition of an 
mTORC1 inhibitor would even be counterproductive103. 
 
Pyrimidine metabolism 
The pyrimidine ring is assembled before it is condensed with PRPP. The initial steps of 
pyrimidine synthesis are carried out by the trifunctional enzyme carbamoyl phosphate 
synthetase 2, aspartate transcarbamylase and dihydroorotase (CAD) (Fig. 4), which uses 
glutamine, aspartate, bicarbonate (HCO3−) and ATP for the formation of 
dihydroorotate (DHO). DHO dehydrogenase (DHOD) converts DHO to orotate, which 
combines with PRPP to form orotate monophosphate (OMP), the precursor for all 
pyrimidine nucleotides (Fig. 4). CAD is a MYC target104 and is post-translationally 
regulated by mTORC1. The mTORC1 effector S6K phosphorylates CAD to promote 
CAD oligomerization and ultimately pyrimidine synthesis105,106. 
 
Interestingly, pyrimidine synthesis is also coupled to alterations in arginine metabolism. 
Carbamoyl phosphate is synthesized by the carbamoyl phosphate synthetase 2 moiety of 
CAD and by CPS1 in mitochondria. CPS1 expression, like mTORC1 signalling, is 
inhibited by liver kinase B1 (LKB1; also known as STK11)–AMPK signalling107,108 
(Fig. 1). In NSCLC cells with oncogenic KRAS and loss of LKB1, mTORC1 is 
activated107, and elevated CPS1 expression enables CPS1 to unconventionally produce 
carbamoyl phosphate for pyrimidine nucleotide synthesis108. Furthermore, the amino 
acid aspartate has emerged as another positive regulator of mTORC1 activity through 
its role in pyrimidine synthesis. Aspartate is used by ASS1 in the urea cycle and by 
CAD in pyrimidine synthesis. ASS1-deficient cancer cells are unable to use aspartate in 
the urea cycle, making more aspartate available for the production of pyrimidines41. 
Indeed, knockdown of ASS1 in osteosarcoma cell lines increases intracellular aspartate 
levels, which promotes CAD activity and thereby increases pyrimidine synthesis and 
proliferation41. Therefore, combining inhibition of mTORC1 and inhibition of 
pyrimidine synthesis could be an effective cancer therapy. While this has not been 
tested directly, studies indicate that treatments that indirectly reduce mTORC1 activity 
can act synergistically with inhibition of pyrimidine synthesis. Indeed, a combination of 
ADI-PEG20 treatment (which decreases the levels of arginine109 and thereby mTORC1 
activity, as arginine is a potent activator of mTORC1) and inhibition of pyrimidine 
synthesis by 5-flurouracil is synergistic in ASS1-deficient HCC cell lines110.  
 
mTOR and fatty acid and lipid metabolism 
Fatty acid metabolism 
Cells acquire fatty acids through uptake or via de novo synthesis, and both processes are 
often upregulated in cancer111 (Fig. 5). Both fatty acid synthesis and fatty acid uptake 
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are stimulated in response to mTOR signalling. As such, both mTORC1 and mTORC2 
stimulate expression and proteolytic processing of SREBP1, the main transcription 
factor that induces fatty acid synthesis enzymes including ATP citrate lyase (ACLY), 
acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN) and stearoyl-CoA 
desaturase 1 (SCD1; also known as SCD) and the fatty acid transporter CD36 
(refs112,113,114,115) (Fig. 5). Furthermore, mTORC1 promotes SREBP1 activity by 
preventing the nuclear entry of LIPIN1, a negative regulator of SREBP1, in several cell 
lines, including a liver cancer cell line116. In renal angiomyolipoma cell lines, 
mTORC1–S6K signalling increases splicing and stability of FASN, ACLY and SCD1 
transcripts through phosphorylation and activation of serine/arginine-rich protein kinase 
2 (SRPK2)117. mTORC2, via its downstream effector AKT, promotes SREBP1 
expression114,118 and prevents SREBP1 degradation in cancer cells119. In mice deficient 
for both PTEN and TSC1, mTORC2 drives liver cancer, at least in part by activating 
SREBP1 (ref.118) (Fig. 5). Lastly, mTORC2 also phosphorylates and activates ACLY, 
thereby supporting the growth of HER2 (also known as ERBB2)-positive and PI3K-
mutant breast cancer cell lines120. 
 
Notably, MYC also regulates ACC1, FASN and SCD1 expression in cancer121. In 
addition, MYC promotes TCA cycle enzyme expression to increase the production of 
citrate, the precursor for de novo fatty acid synthesis122 (Fig. 5). Accordingly, the 
targeting of fatty acid synthesis has been exploited as an anticancer strategy, and 
inhibitors of FASN, the rate-limiting enzyme in fatty acid synthesis, have entered 
clinical trials. For example, TVB-2640, the first oral and selective FASN inhibitor, has 
recently entered clinical trials for several solid tumours, including colon cancer, breast 
cancer and astrocytoma123,124,125,126 (Table 1). Another FASN inhibitor, epigallocatechin 
gallate (EGCG), will be tested in patients with colorectal cancer127 (Table 1). 
 
One obstacle in targeting FASN is that cancer cells might be able to circumvent 
inhibition of fatty acid synthesis by increasing fatty acid uptake through expression of 
fatty acid transporters such as CD36. Targeting mTOR signalling, because it promotes 
both fatty acid uptake and fatty acid synthesis, might be a strategy to overcome potential 
resistance mechanisms. mTOR inhibition alone might not be effective owing to mTOR-
independent inputs from other signalling pathways. These include MYC-mediated 
expression of fatty acid synthesis genes121, AKT-independent phosphorylation of 
ACLY128 and induction of the fatty acid synthesis-promoting transcription factor 
carbohydrate responsive element binding protein (ChREBP), which is upregulated in 
certain cancers129. Thus, combining fatty acid synthesis and mTOR inhibitors might 
prove beneficial for patients with cancer. This notion is supported by a preclinical study 
that reported synergistic effects of the mTORC1 inhibitor rapamycin in combination 
with an FASN inhibitor in breast cancer cells130. 
 
Lipid metabolism 
Cancer cells require lipids, including glycerophospholipids, sphingolipids and sterols, 
for membrane synthesis and signalling (second messengers) (Fig. 5). The mTOR-
controlled transcription factor SREBP1 stimulates expression of elongation of very long 
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chain fatty acids (ELOVL) to promote elongation of polyunsaturated fatty acids, which 
are the immediate precursors for synthesis of many lipids131. mTORC1 promotes 
synthesis of the lipid phosphatidylcholine by activating the rate-limiting enzyme 
phosphocholine cytidylyltransferase-α (CCTα; also known as PCYT1A)132, which is 
also under the transcriptional control of SREBP1 (ref.131). 
 
Sphingolipids, such as ceramides or sphingosine-1-phosphate (S1P), have important 
signalling functions (Fig. 5). Ceramides suppress cancer cell growth, in part by reducing 
AKT activity133. Cancer cells thus employ various mechanisms to prevent ceramide 
accumulation. These mechanisms include upregulation of glucosylceramide synthase 
(GCS) (which converts ceramide to glycosylceramide), among others134 (Fig. 5). In a 
PTEN-deficient and TSC1-deficient mouse model for HCC, mTORC2 stimulates 
tumorigenesis by promoting expression of GCS, thereby preventing ceramide 
accumulation. Knockdown of GCS in the mouse model prevents HCC tumorigenesis118. 
 
In contrast to ceramide, S1P promotes cell proliferation and migration. Many cancers, 
including breast, colon, lung and renal carcinoma, increase sphingosine kinase 1 
(SPHK1) expression, which leads to increased S1P levels135. SPHK1–S1P signalling, 
which is activated upon hypoxia, promotes cancer cell proliferation and migration, at 
least in part by activating mTOR signalling135,136. 
 
Specific sphingolipid synthesis inhibitors are now being evaluated in preclinical and 
early-phase clinical trials as anticancer agents. Myriocin, a serine palmitoyltransferase 
(SPT) inhibitor, reduces proliferation of lung cancer and melanoma cell lines137 and 
attenuates HCC in mice118. Furthermore, the SPHK2 inhibitor ABC294640 is in clinical 
trials for cholangiocarcinoma138, multiple myeloma139 and advanced HCC140 (Table 1). 
Interestingly, ABC294640 reduces mTORC1 and mTORC2 activity in colorectal 




Notably, in addition to the process described above, recent work has revealed links 
between mTOR signalling and metabolism of amino acids that have not been 
recognized as activators of mTORC1, that is, amino acids other than glutamine, arginine 
and leucine. For example, mTORC1 promotes serine biosynthesis100,142,143; mTORC2 
regulates the cystine–glutamate antiporter xCT (also known as SLC7A11), which is 
upregulated in triple-negative breast cancer and GBM144, and a subset of cancer cells 
depends on proline uptake to sustain mTORC1–4EBP signalling145. In addition to 
amino acids, other metabolites have recently been described to modulate mTORC1 
activity, including S-adenosyl-methionine (SAM)146, purine nucleotides101,102 and 
cholesterol147. Conversely, mTOR signalling regulates multiple aspects of nucleotide, 
fatty acid and lipid metabolism (see above). These findings further suggest that mTOR 
inhibitors could be considered for cancers with mTOR-related metabolic alterations. 
To pursue such a strategy, it is important to understand further the mutual determinism 
of metabolic reprogramming and mTOR signalling. It might also be necessary to revise 
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our view of how driver mutations determine tumour development and metabolic 
alterations. A recently proposed concept is that the tissue of origin rather than 
underlying mutations dictates how cancer cells reprogramme their metabolism148. 
Therefore, it will be necessary to define the metabolic signatures for cancer subtypes to 
classify patients for treatment options. Such classifications might also reveal how 
metabolic vulnerabilities can be therapeutically exploited. For example, in LSCC, a 
metabolic signature has been suggested to predict responsiveness or resistance to mTOR 
inhibitors30. Several drugs, such as metformin, dichloracetate149 or disulfiram150, that 
interfere with cellular metabolism and have been used to treat metabolic diseases for 
many years are now being repurposed for cancer treatment. For example, metformin, 
the most frequently prescribed drug for the treatment of type 2 diabetes, activates 
AMPK, inhibits mTORC1 (ref.151) and attenuates protein synthesis, the TCA cycle and 
nucleotide synthesis152. Thus, metformin, alone or in combination with other cancer 
drugs, has been shown to be effective in reducing tumour growth in several models153–
155. Indeed, metformin is currently in a number of clinical trials, including in 
combination with mTORC1 inhibitors156–158 (Table 1). 
 
Several clinical trials are now evaluating the use of mTOR inhibitors in combination 
with other targeted drugs that interfere with cancer cell metabolism. However, to 
optimize treatment strategies, we will need to understand how anticancer drugs targeting 
metabolism affect cancer and non- cancer cells in the tumour microenvironment, which 
could help, for example, to avoid drug- induced immunosuppression (Box 1). As such, 
therapeutic strategies that aim at arginine or glucose deprivation will also inhibit T cell 
activation and proliferation, thereby probably precluding an adequate immune response 
towards the tumour. Members of the first generation of mTOR inhibitors and drugs 
targeting metabolic alterations have had weak therapeutic efficacy as single agents (for 
extended reading on mTOR inhibitors, see refs18,159 for reviews). Secondgeneration 
mTOR inhibitors are currently being tested, and more drugs interfering with metabolic 
alterations are being developed. The extensive interplay between mTOR signalling and 
metabolic reprogramming strongly supports further exploration of combinations of 
drugs targeting metabolism with mTOR inhibitors. 
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Fig. 1: Activation of mTOR signalling 
 
Growth factors (for example, insulin) bind to receptor tyrosine kinases (RTKs) to activate PI3K. PI3K 
converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), which is counteracted by PTEN. For activation of mTOR complex 2 (mTORC2), PIP3 binds 
mammalian stress-activated MAPK-interacting protein 1 (mSIN1). For activation of mTORC1, PIP3 
recruits phosphoinositide-dependent kinase 1 (PDK1) to activate AKT. AKT inhibits the TSC complex, 
which acts as GTPase-activating protein (GAP) on the GTPase RHEB. GTP-bound RHEB binds and 
activates mTORC1. Energy stress activates liver kinase B1 (LKB1) and AMP-activated kinase 
(AMPK) to suppress mTORC1 via inhibition of regulatory-associated protein of mTOR (RAPTOR) 
and activation of the TSC complex107. Full activation of mTORC1 requires signalling induced by 
amino acids. SLC7A1, SLC7A5, SLC1A5 and other transporters import amino acids into the cell. Once 
in the cytoplasm, amino acids can induce activation of RAS-related GTP-binding proteins (RAGs), 
which mediate lysosomal translocation of mTORC1. RAGULATOR binds the RAGs at the lysosome 
and acts as a guanine nucleotide exchange factor towards RAGA and/or RAGB165. GAP activity 
towards RAGS 1 (GATOR1) inactivates RAGA and/or RAGB166. KICSTOR recruits and binds 
GATOR1 (ref.167). GATOR2 is required for mTORC1 activation and was suggested to bind and inhibit 
GATOR1. Leucine can promote mTORC1 activation via binding to sestrin 2 and/or sensing by LeuRS. 
Arginine binds to CASTOR1. Both sestrin 2 and CASTOR1 release inhibition of GATOR2 (ref.10). 
Glutamine activates mTORC1 in a RAG-dependent manner via glutaminolysis and in a RAG-
independent manner via the small GTPase ARF1. The lysosomal transporter SLC38A9 exports 
essential amino acids into the cytosol in an arginine-stimulated fashion11. Amino acids signal through 
folliculin (FLCN) and FLCN-interacting protein 1 (FNIP1) or FNIP2, which act as GAPs for RAGC 
and/or RAGD168. S-adenosyl-methionine (SAM) prevents SAMTOR binding to GATOR1 and 
KICSTOR146. Light red-coloured molecules indicate negative and purple coloured molecules indicate 
positive regulators of mTOR signalling. Turquoise arrows indicate metabolite flux, while black arrows 
indicate a signalling cascade. Dashed lines indicate indirect actions or that it is unknown whether 
additional steps are required. αKG, α-ketoglutarate; GDH, glutamate dehydrogenase; GLS, 







Fig. 2: mTOR-driven reprogramming of amino acid metabolism 
 
a | Glutamine metabolism. SLC1A5, SLC38A1, SLC38A2 and SLC38A5 mediate glutamine uptake. 
Glutamine, which contributes to activation of mTOR complex 1 (mTORC1), is converted to glutamate 
and α-ketoglutarate (αKG) by glutaminase (GLS) and glutamate dehydrogenase (GDH). mTORC1 
phosphorylates and thereby activates ribosomal protein S6 kinase (S6K). S6K promotes MYC 
translation, which derepresses GLS by inhibiting miR-23a and miR-23b. mTORC1 also induces 
proteasome-dependent degradation of cAMP-responsive element binding 2 (CREB2), a transcription 
factor that induces sirtuin 4 (SIRT4) expression. SIRT4 inhibits GDH by ADP ribosylation. Glutamine 
synthetase (GS) converts glutamate to glutamine. GS expression is promoted by FOXO3 and/or 
FOXO4, which are potentially under negative control of mTORC2. b | Arginine metabolism. SLC7A1 
mediates arginine uptake. Carbamoyl phosphate synthetase 1 (CPS1) produces carbamoyl phosphate, 
which condenses with ornithine to form citrulline. Argininosuccinate synthetase 1 (ASS1) ligates 
citrulline and aspartate to form argininosuccinate. Argininosuccinate is cleaved to arginine and 
fumarate by argininosuccinate lyase (ASL). Arginine is cleaved to urea and ornithine by cytosolic 
arginase 1 (ARG1) or mitochondrial arginase 2 (ARG2). During polyamine synthesis, ornithine is 
decarboxylated by ornithine decarboxylase (ODC) to form putrescine. Putrescine serves as the 
precursor for the formation of the polyamines spermidine and spermine. Adenosylmethionine 
decarboxylase 1 (AMD1) decarboxylates S-adenosyl-methionine (SAM) to decarboxylated SAM 
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(decSAM), which is required for polyamine synthesis. mTORC1 and/or mTORC2 promote reactions as 
shown. c | Branched chain amino acid (BCAA) metabolism. SLC7A5 and SLC43A1 mediate BCAA 
uptake. Branched chain aminotransferase 1 (BCAT1) or BCAT2 mediate interconversion of BCAAs 
and branched chain ketoacids (BCKAs). BCKAs are decarboxylated by BCKA dehydrogenase 
(BCKD), and further catabolism results in formation of acetyl-CoA and succinyl-CoA, which enter the 
tricarboxylic acid (TCA) cycle. mTORC1 may promote BCAA uptake. Turquoise arrows indicate 
metabolite flux, while black arrows indicate a signalling cascade. Dashed lines indicate indirect actions 
or that it is unknown whether additional steps are required. 4EBP, eIF4E binding protein; HCO3-, 




Fig. 3: mTOR controls glucose metabolism in cancer 
 
Glucose transporter 1 (GLUT1) mediates glucose uptake. Glucose is phosphorylated by hexokinase 2 
(HK2) to form glucose-6-phosphate (G6P), which can be diverted into the pentose phosphate pathway 
(PPP). Phosphoglucoisomerase (PGI) isomerizes G6P to fructose-6-phosphate (F6P), which is further 
phosphorylated by phosphofructokinase (PFK) to form fructose-1,6-bisphosphate (F1,6BP). Multiple 
enzymatic steps lead to the formation of 2-phosphoglycerate (2PG), which is converted to 
phosphoenolpyruvate (PEP) by enolase (ENO). In the last step of glycolysis, PEP is converted to 
pyruvate by pyruvate kinase muscle isoform 2 (PKM2). Lactate dehydrogenase (LDH) interconverts 
pyruvate and lactate. mTOR complex 1 (mTORC1) and/or mTORC2 promote glycolysis by direct 
mechanisms or indirectly by induction of the transcription factors MYC and/or hypoxia-inducible 
factor 1α (HIF1α). PKM2 also acts back on mTORC1 by promoting serine biosynthesis and by 
inhibiting proline-rich AKT substrate 1 (PRAS40), a negative regulator of mTORC1. Turquoise arrows 
indicate metabolite flux, while black arrows indicate a signalling cascade. Dashed lines indicate indirect 
actions or that it is unknown whether additional steps are required. TCA, tricarboxylic acid. 
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Fig. 4: Rewiring of nucleotide metabolism by mTOR 
 
Glucose-6-phosphate (G6P) derived from glycolysis fuels the pentose phosphate pathway (PPP) to 
generate ribose-5-phosphate (R5P) for nucleotide synthesis. The PPP is divided into an oxidative and a 
non-oxidative branch (ox. PPP and non-ox. PPP, respectively), which involve enzymes such as G6P 
dehydrogenase (G6PD) and R5P isomerase A (RPIA), both of which are stimulated by mTOR complex 
1 (mTORC1). Phosphoribosyl pyrophosphate synthase 2 (PRPS2) ultimately generates ribose-5-
phosphoribosyl-1-pyrophosphate (PRPP) from R5P and is induced by mTORC1 and mTORC2 through 
independent mechanisms, as shown. Purine synthesis requires glutamine, glycine, aspartate, formyl-
tetrahydrofolate (fTHF) and CO2. The formation of fTHF is promoted by mTORC1 through 
methylenetetrahydrofolate dehydrogenase 2 (MTHFD2). The purine ring is assembled directly on 
PRPP. Multiple enzymes, including glycinamide ribonucleotide formyltransferase (GARFT), lead to 
the formation of inosine monophosphate (IMP). IMP is further converted to different forms of purine 
nucleotides. The formation of some purine nucleotides requires IMP dehydrogenase 2 (IMPDH2). 
Assembly of the pyrimidine ring requires glutamine, aspartate, ATP and bicarbonate (HCO3−). Initial 
steps are carried out by carbamoyl phosphate synthetase 2, aspartate transcarbamylase and 
dihydroorotase (CAD) to form dihydroorotate (DHO). mTORC1, via ribosomal protein S6 kinase 
(S6K), promotes CAD activity. Orotate is combined with PRPP to generate orotidine monophosphate 
(OMP). OMP is the precursor for all pyrimidine nucleotides. Turquoise arrows indicate metabolite flux, 
while black arrows indicate a signalling cascade. Dashed lines indicate indirect actions or that it is 
unknown whether additional steps are required. 3PG, 3-phosphoglycerate; DHOD, DHO 




Fig. 5: Regulation of fatty acid and lipid metabolism 
 
CD36 mediates fatty acid uptake. For de novo fatty acid synthesis, ATP citrate lyase (ACLY) converts 
citrate derived from the tricarboxylic acid cycle (TCA) cycle, for example, to acetyl-CoA. Acetyl-CoA 
carboxylase 1 (ACC1) catalyses the carboxylation of acetyl-CoA to malonyl-CoA. Fatty acid synthase 
(FASN) synthesizes the fatty acid palmitate by condensing acetyl-CoA groups with malonyl-CoA. 
Elongation and desaturation reactions starting from palmitate result in different fatty acid species. 
Lysophosphatidic acid (LPA) is synthesized from fatty acyl-CoA and 3-phosphoglycerate (3PG). 
Addition of another fatty acyl-CoA molecule leads to the formation of diacylglycerol (DAG). DAG can 
be converted into different phosphoglycerides, for example, phosphatidylcholine. mTOR complex 1 
(mTORC1) promotes phosphatidylcholine synthesis by stimulating phosphocholine 
cytidylyltransferase-α (CCTα). In de novo sphingolipid synthesis, palmitoyl-CoA is converted into 
ceramide through multiple enzymatic reactions involving serine palmitoyltransferase (SPT). Ceramide 
serves as a precursor for at least four different sphingolipid species (sphingomyelin, sphingosine, 
ceramide-1-phosphate and glucosylceramide). Glucosylceramide synthase (GCS) converts ceramide to 
glucosylceramide, which can be promoted by mTORC2. In addition, ceramide is sequentially 
converted to sphingosine and phosphorylated by sphingosine kinase 1 (SPHK1) to form sphingosine-1-
phosphate (S1P). S1P can promote mTORC1 and mTORC2 signalling. Turquoise arrows indicate 
metabolite flux, while black arrows indicate a signalling cascade. Dashed lines indicate indirect actions 
or that it is unknown whether additional steps are required. ELOVL, elongation of very long chain fatty 
acids; S6K, ribosomal protein S6 kinase; SREBP1, sterol regulatory element binding protein 1; SRPK2, 





Table 1 Ongoing clinical trials of drugs targeting cancer metabolism 
Target molecule or pathway Drug name Cancer type Refs 
Amino acid metabolism 
GLS CB-839 Breast cancer 32 




CB-839 + everolimusa RCC 169 
Arginine rhARG1 Acute myeloid leukaemia 44 
HCC, RCC, melanoma and 
prostate adenocarcinoma 
45 
ADI-PEG20 Prostate cancer and NSCLC 46 
Advanced solid tumour 47 
Glucose metabolism 
MCT1 AZD-3965 Prostate cancer, gastric cancer 
and diffuse large B cell 
lymphoma 
93 
Fatty acid metabolism 
FASN TVB-2640 Solid malignant tumour 124 
Colon cancer 123 
Breast cancer 125 
Astrocytoma 126 
EGCG Colorectal cancer 127 
SPHK2 ABC294640 Advanced cholangiocarcinoma 138 
Multiple myeloma 139 
Advanced HCC 140 
Glucose and fatty acidmetabolism 
Glycolysis and fatty acid synthesis Metformin + temsirolimusa Advanced cancers 156 
Metformin + rapamycin Breast neoplasms, lung neoplasms, 
liver cancer, lymphoma and kidney 
cancer 
157 
Pancreatic cancer 158 
ADI-PEG20, pegylated arginine deiminase; EGCG, epigallocatechin gallate; FASN, fatty acid 
synthase; GLS, glutaminase; HCC, hepatocellular carcinoma; MCT1, monocarboxylate transporter 1; 
NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; rhARG1, recombinant human 







Box 1 mTOR signalling and metabolic flux in the tumour microenvironment 
Recent studies have revealed extensive signalling and metabolic flux between tumour cells and nearby 
non-tumour cells, such as fibroblasts or T cells (see the figure). 
Fibroblasts 
In pancreatic ductal adenocarcinoma (PDAC), cancer-associated fibroblasts (CAFs) support tumour 
cell growth by secreting non-essential amino acids, in particular, alanine. PDAC cells use alanine to 
fuel the tricarboxylic acid (TCA) cycle and to synthesize lipids. This alanine flux within the tumour 
microenvironment (TME) enables the tumour cells to divert glucose for the synthesis of non-essential 
amino acids, such as serine and glycine, which are required for nucleotide synthesis160. Whether mTOR 
signalling is involved in this metabolic modulation is not known; however, CAFs in PDAC possess 
high mTOR activity161. If it is, the use of an mTOR inhibitor might be beneficial, as it would inhibit 
CAFs and thereby interrupt metabolic flux between CAFs and tumour cells. 
T cells 
Amino acid flux. Cancer cells counter immune cells by depleting the TME of specific amino acids. 
Secretion of cytosolic arginase 1 (ARG1) or mitochondrial arginase 2 (ARG2) leads to reduced levels 
of arginine and inhibition of T cells in the TME162. Overexpression of indoleamine-2,3-dioxygenase 1 
(IDO1) and tryptophan-2,3-dioxygenase 2 (TDO2) leads to the conversion of the essential amino acid 
tryptophan into kynurenine. While tryptophan deprivation triggers apoptosis of T cells in the TME, 
secreted kynurenine promotes a regulatory T cell phenotype, which further inhibits immune 
responses163. 
Glycolytic flux. In a mouse sarcoma model, tumour cells outcompete T cells for glucose. This leads to 
sustained mTOR signalling and glycolysis in the tumour cells and, as a consequence, tumour 
progression. Conversely, decreased mTOR signalling, glycolysis and chemokine secretion in the T cells 
prevent the T cells from checking tumour progression164. Furthermore, as a result of increased 
glycolysis, tumour cells often secrete lactate via monocarboxylate transporter 4 (MCT4), which affects 
the TME by promoting immunosuppression and angiogenesis163. 
Metabolic symbiosis via lactate 
mTOR-dependent metabolic symbiosis between cancer cells, in which cancer cells can take up lactate 
from the TME via MCT1 and use it for metabolism, also occurs, as further described in the main 
text91,92. 
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